Ginkgo Bioworks Q2 revenue falls 11%
Overview
Ginkgo Q2 2025 rev falls to $50 mln, down from $56 mln yr/yr
Cell Engineering rev rises 8% to $39 mln, driven by biopharma growth
Biosecurity rev declines to $10 mln from $20 mln yr/yr
Co achieves $250 mln cost-reduction target ahead of schedule
Outlook
Ginkgo reaffirms 2025 total revenue of $167-$187 mln
Ginkgo expects 2025 Cell Engineering revenue of $117-$137 mln
Ginkgo expects 2025 Biosecurity revenue of at least $40 mln
Ginkgo aims for Adjusted EBITDA breakeven by end of 2026
Result Drivers
CELL ENGINEERING GROWTH - Cell Engineering revenue rose 8% to $39 mln, driven by demand from biopharma and government customers
BIOSECURITY DECLINE - Biosecurity revenue fell to $10 mln, impacted by reduced demand compared to prior year
COST REDUCTION - Achieved $250 mln annualized cost-reduction target ahead of schedule, aiding improved adjusted EBITDA
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Rev | $50 mln | ||
Q2 EPS | -$1.1 | ||
Q2 Net Income | -$60.30 mln | ||
Q2 Operating Expenses | $115.14 mln | ||
Q2 Operating Income | -$65.54 mln | ||
Q2 Pretax Profit | -$60.58 mln |
Analyst Coverage
The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00, about 74.5% below its August 6 closing price of $13.96
Press Release:
